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Abstract
Background—Serologic tests for syphilis (STS) results at time of diagnosis are the basis for
evaluating response to syphilis therapy. Following treatment, however, STS titers may continue to
increase for several weeks. We evaluated RPR titer variation over the 14 days following therapy
using data from a recent large, prospective RCT.
Methods—Prospectively enrolled participants in North America and Madagascar with primary,
secondary or early latent syphilis were randomly assigned to penicillin, doxycycline (in the case of
penicillin allergy) or azithromycin treatment. Blood for RPR analysis was drawn at days 0, 7, and
14 post-treatment. All RPR titers were determined simultaneously at a central laboratory.
Results—470 patients had data available for at least 2 of 3 RPR measurements. Overall, 20% of
patients showed a titer increase of at least one dilution in the 14 days following therapy. The
greatest proportion of titer increases following therapy was seen in patients with primary syphilis.
Comparing outcome of therapy using the initial (day 0) RPR titer vs. the maximal RPR titer (over
14 days), resulted in outcome reclassification in 2.98% of participants.
Conclusions—Despite the fact that about 20% of early syphilis patients had increases in RPR
titers immediately following treatment, these changes rarely influenced assessment of therapeutic
outcome. Only 3% of patients treated would have been reclassified.
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Introduction
Syphilis is a relatively common, chronic infectious disease of public health importance. In
addition to direct morbidity associated with infection, syphilis may be transmitted to sexual
partners and to unborn children of infected mothers. Syphilis also is associated with
increased risk for HIV transmission.[1] U.S. syphilis rates have risen steadily through the
last decade.[2]
Serological testing for antibodies against Treponema pallidum is the most widely used
means for syphilis diagnosis. Repeated determination of non-treponemal (i.e. RPR, VDRL)
serologic test for syphilis (STS) titers is recommended to evaluate response, with a four-fold
(2 dilution) decrease from baseline and/or seroreversion in 12 months following treatment
representing an appropriate response to therapy/serologic cure.[3] In most settings, the non-
treponemal STS titer present at treatment is used to evaluate subsequent therapeutic
response. However, it is possible that anti-treponemal antibody concentrations may continue
to increase for a period of time following effective therapy.[4] To evaluate the frequency
with which STS titers increased following early syphilis therapy, we analyzed weekly
serologic test results obtained on three occasions from over 400 patients in a recent
therapeutic trial that compared benzathine penicillin G to azithromycin for early syphilis
therapy.
Methods
Data collected as part of an open-label, randomized controlled trial conducted from June
2000-March 2009 at five sexually transmitted disease clinics in North America and three
clinics in Madagascar were analyzed. Methods, including details regarding recruitment,
therapeutic intervention, and clinical assessment, were previously described.[5] The protocol
was approved by the Institutional Review Board (IRB) at the University of Alabama at
Birmingham (UAB) and at each participating site.
Briefly, participants with primary, secondary or early latent syphilis were randomized to
treatment with single doses of benzathine penicillin 2.4 million units intramuscularly or
azithromycin 2.0 grams. Participants with reported penicillin allergy were randomized to
doxycycline 100 milligrams orally twice daily for fourteen days or azithromycin 2.0 grams
orally. Follow up visits for RPR testing were scheduled at 7 and 14 days, and 3 and 6
months following treatment. Sera to determine study-defined treatment outcomes were
stored frozen and all RPR testing was performed same day at the UAB central laboratory
according to accepted methods.[6]
The primary outcome of the trial was serological response to therapy at 6 months. To
evaluate response to treatment, the maximal RPR titer during three visits occurring in the 14
days following therapy (i.e. day of treatment, 7 days and 14 days) was used as the baseline
for analysis. Serological cure was defined as either negative RPR or ≥4-fold (2 dilutions)
decrease in titer (no participants had recurrent signs of infection); treatment failure was
defined as ≥4-fold increase in RPR titer without clear history of re-exposure. Serological
non-response or serofast status was defined as no more than a 2-fold (1 dilution) increase or
decrease from baseline. As specified in the protocol, those participants defined as treatment
failure or serological non-response were retreated at 6 months with benzathine penicillin or
doxycycline, if penicillin allergic.
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The study population for this report is participants with serological data at the 6 months visit
post treatment and without a change in eligibility status prior to the 6 month visit. Statistical
analysis was performed using SAS Software Version 9.2.[7] P-values are based on chi-
square tests obtained from relevant contingency tables. We determined the proportions of
participants with an increase in RPR titer during the 14 days following syphilis therapy.
Results
A total of 470/517 (90.9%) patients had data for at least 2 of 3 RPR measurements during
their first two weeks of study participation and completed the six-month follow up without a
change in protocol status. Selected demographic characteristics are presented in Table 1.
Median RPRs at diagnosis, stratified by stage, were Primary 1:16, Secondary 1:64, and
Early Latent 1:32.(Figure 1) Overall, 20.2% (95) of patients showed a titer increase in the 14
days following therapy.(Table 2) Of these, 88.2% (84) demonstrated an increase of 1
dilution, while in 11.8% (11) RPR titers increased ≥2 dilutions. Persons with the earliest
stages of syphilis were more likely to experience RPR increases in the two weeks following
therapy, with 30.5% of participants treated for primary syphilis experiencing an increase in
RPR titers, while the proportion of secondary and early latent syphilis patients was about
17% and 16%, respectively.(p=0.005)
We compared the outcome of therapy (i.e. cure, serofast, failure) at 6 months using both a
“clinical definition,” the initial titer at the time of treatment, and a “research definition,” the
maximal titer obtained during the 14 days following treatment. When the two definitions
were compared, the outcome changed in only 14 participants (2.98%). Thirteen changed
from serofast (clinical) to cure (research) and one changed from failure (clinical) to serofast
(research). (Table 3) Increased RPR titers in the two weeks following therapy did not occur
in all patients with treatment failure. Of the five participants classified as serological
treatment failures[5], only one had a single dilution rise in RPR titer in the 14 days
following therapy. However at the time of defined treatment failure, this patient’s RPR titer
had increased by 3 dilutions from the initial titer.
Selected characteristics of participants with a rise in RPR titer following treatment were
compared to those without a rise in titer. Earlier syphilis stage was the only variable
significantly associated with an increase in RPR titer following therapy.(Table 1) Age,
gender, treatment regimen, ethnicity (Malagasy vs. non-Malagasy), prior syphilis and
Jarisch-Herxheimer reaction were not significantly associated with an increase in RPR titer
during the 14 days following treatment.
Discussion
To our knowledge, these data represent the first systematic analyses of RPR increases in
humans immediately following therapy of early syphilis. We found that initial RPR titers
underestimate the maximal RPR titer in about 20% of early syphilis patients following
therapy. In particular, earlier stage is associated with an increase in RPR titer, while age,
gender, ethnicity, treatment regimen, prior syphilis, or a Jarisch-Herxheimer reaction were
not significantly associated. Using the RPR titer measured at the time of treatment as the
baseline to assess serologic response resulted in re-classification of ~3% of patients, slightly
underestimating cures and overestimating failures.
While we acknowledge the relatively limited clinical implications, our study quantifies the
frequency of increase in RPR titers in the weeks immediately following early syphilis
therapy. While the CDC STD Treatment Guidelines recommend follow up of non-
treponemal serologic tests of syphilis patients at 6 and 12 months following therapy[3], from
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time to time patients have repeat syphilis testing prior to these specified times. In our
experience, this situation can result in confusion about the appropriate next step. Our data
suggest that a rise in RPR titer within the 14 days following early syphilis therapy is not
indicative of increased risk of treatment failure and does not require additional therapy or
change in management.
We acknowledge several study limitations. Combining the azithromycin and penicillin
treatment arms raises concern for possible effects; however, our analysis did not reveal a
significant effect on RPR titer increase. We also acknowledge that in clinical settings where
syphilis patients are tested repeatedly, RPR or VDRL titers may vary +/- 1 dilution. We
sought to minimize variability by testing all serum simultaneously in a single laboratory.
Nonetheless, some of the observed variations may reflect the acknowledged error of the test.
We also excluded pregnant or HIV positive patients, limiting the generalizability to these
groups. We collected data regarding treatment response up to 6 months; it is conceivable
that outcomes may have differed if additional data was collected past that time point.
Finally, as only patients with early syphilis were enrolled, these findings are not applicable
for patients with late stages of syphilis.
These data also have implications for the research setting. Given that RPR titers increase in
about 20% of participants with early syphilis, testing several times over the two weeks
immediately following therapy will provide the most accurate peak titer for subsequent
assessment of response to therapy. Had the initial RPR at time of treatment been used as the
baseline for therapeutic response at 6 months, ~3% of patients treated would not have met
criteria for serologic cure.
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Distribution of RPR Titers at Day of Treatment (Visit 1) by Stage
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Table 1
Characteristics of Patients With and Without RPR Titer Increase In the 14 Days Following Early Syphilis
Treatment
Characteristic No RPR Titer Increase (N=375), n(%) RPR Titer Increase (N=95), n(%) OR (95%CI)
Gender
 Male 226 (77.9) 64 (22.1) 1.36 (0.85, 2.19)
 Female 149 (82.8) 31(17.2) 1
Age (years)
 </=24 180 (77.9) 51(22.1) 1.39 (0.63, 3.03)
 25-29 78 (76.5) 24(23.5) 1.50 (0.64, 3.52)
 30-39 73 (86.9) 11 (13.1) 0.74 (0.28, 1.92)
 >/=40 44 (83.0) 9 (17.0) 1
Race/ ethnicity
 Black 56 (87.5) 8 (12.5) 1
 White + other 10 (71.4) 4 (28.6) 2.80 (0.71, 11.1)
 Malagasy 309 (78.8) 83 (21.2) 1.88 (0.86, 4.10)
Prior history of syphilis
 No 65 (84.4) 12 (15.6) 1
 Yes 27 (84.4) 5 (15.6) 1.00 (0.32, 3.12)
 Unknown/ Test not performed 283 (78.4) 78 (21.6) 1.49 (0.77, 2.90)
Syphilis Stage
 Primary 82 (69.5) 36 (30.5) 1
 Secondary 181 (82.7) 38 (17.3) 0.48 (0.28, 0.81)
 Early Latent 112 (84.2) 21 (15.8) 0.43 (0.23, 0.79)
Jarisch-Herxheimer Reaction
 No 231 (79.4) 60 (20.6) 1
 Yes 143 (80.3) 35 (19.7) 0.94 (0.59, 1.50)
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Table 2
By Stage, Percentage of Patients with an Increase in RPR Titers in the 14 Days Following Therapy of Early
Syphilis.
Stage N Median RPR atdiagnosis
% with increased titers within 14 days
following treatment (95% CI)
% with titers increased by ≥2 dilutions
following therapy (95% CI)
Primary 118 1:16 30.5 (22.4-39.7) 5.9 (2.4-11.8)
Secondary 219 1:64 17.4 (12.6-23.0) 0.5 (0.0-2.5)
Early Latent 133 1:32 15.8 (10.0-23.1) 2.3 (0.5-6.5)
Total 470 1:64 20.2 (16.7-24.1) 2.3 (1.2-4.1)
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